• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肠胃外和粘膜重组益生菌疫苗对动物模型中 SARS-CoV-2 及感染的比较疗效

Comparative Efficacy of Parenteral and Mucosal Recombinant Probiotic Vaccines Against SARS-CoV-2 and Infections in Animal Models.

作者信息

Leontieva Galina, Kramskaya Tatiana, Gupalova Tatiana, Bormotova Elena, Desheva Yulia, Korzhevsky Dmitry, Kirik Olga, Koroleva Irina, Borisevitch Sergey, Suvorov Alexander

机构信息

Scientific and Educational Center "Molecular Bases of Interaction of Microorganisms and Human" of the World-Class Research Center "Center for Personalized Medicine", Federal State Budgetary Scientific Institution «Institute of Experimental Medicine» (FSBSI «IEM»), 197376 Saint Petersburg, Russia.

Federal State Budgetary Science Institute "IEM", 197376 Saint Petersburg, Russia.

出版信息

Vaccines (Basel). 2024 Oct 19;12(10):1195. doi: 10.3390/vaccines12101195.

DOI:10.3390/vaccines12101195
PMID:39460360
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11512341/
Abstract

BACKGROUND

The accumulation of specific IgG antibodies in blood serum is considered a key criterion for the effectiveness of vaccination. For several vaccine-preventable infections, quantitative indicators of the humoral response have been established, which, when reached, provide a high probability of protection against infection. The presence of such a formal correlate of vaccine effectiveness is crucial, for example, in organizing preventive measures and validating newly developed vaccines. However, can effective protection against infection occur when the level of serum antibodies is lower than that provided by parenteral vaccination? Will protection be sufficient if the same vaccine antigen is administered via mucosal membranes without achieving high levels of specific IgG circulating in the blood?

METHODS

In this study, we compared the immunogenicity and protective efficacy of parenteral and mucosal forms of vaccines in experimental animals, targeting infections caused by the SARS-CoV-2 coronavirus and . We investigated the protective properties of a fragment of the coronavirus S1 protein administered intramuscularly with an adjuvant and orally as part of the probiotic strain L3 in a Syrian hamster model. A comparative assessment of the immunogenicity and protective efficacy of a recombinant tandem (PSP) of immunogenic peptides from surface proteins, administered either parenterally or orally, was performed in a Balb/c mouse model.

RESULTS

Both models demonstrated significant differences in the immunogenicity of parenteral and oral vaccine antigens, but comparable protective efficacy.

摘要

背景

血清中特异性IgG抗体的积累被认为是疫苗接种有效性的关键标准。对于几种可通过疫苗预防的感染，已经建立了体液反应的定量指标，达到这些指标时可提供较高的抗感染保护概率。例如，在组织预防措施和验证新开发的疫苗时，这种疫苗有效性的正式关联指标至关重要。然而，当血清抗体水平低于通过胃肠外接种所提供的水平时，能否有效预防感染？如果通过黏膜给药相同的疫苗抗原，而血液中循环的特异性IgG未达到高水平，保护是否足够？

方法

在本研究中，我们比较了疫苗的胃肠外和黏膜形式在实验动物中针对由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）冠状病毒引起的感染的免疫原性和保护效力。我们在叙利亚仓鼠模型中研究了与佐剂一起肌肉注射以及作为益生菌菌株L3的一部分口服的冠状病毒S1蛋白片段的保护特性。在Balb/c小鼠模型中对通过胃肠外或口服方式给药的来自表面蛋白的免疫原性肽的重组串联体（PSP）的免疫原性和保护效力进行了比较评估。

结果

两种模型均显示胃肠外和口服疫苗抗原的免疫原性存在显著差异，但保护效力相当。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/803ffd0f0358/vaccines-12-01195-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/cd16f3fbecf5/vaccines-12-01195-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/6ad1bbacd701/vaccines-12-01195-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/c12a021f19ab/vaccines-12-01195-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/fddfab695685/vaccines-12-01195-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/92afda364a78/vaccines-12-01195-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/1fcf5a0d521f/vaccines-12-01195-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/3a7a256b262b/vaccines-12-01195-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/d32d1d0f18ab/vaccines-12-01195-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/efa9682aa958/vaccines-12-01195-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/34d663827c36/vaccines-12-01195-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/803ffd0f0358/vaccines-12-01195-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/cd16f3fbecf5/vaccines-12-01195-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/6ad1bbacd701/vaccines-12-01195-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/c12a021f19ab/vaccines-12-01195-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/fddfab695685/vaccines-12-01195-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/92afda364a78/vaccines-12-01195-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/1fcf5a0d521f/vaccines-12-01195-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/3a7a256b262b/vaccines-12-01195-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/d32d1d0f18ab/vaccines-12-01195-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/efa9682aa958/vaccines-12-01195-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/34d663827c36/vaccines-12-01195-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a823/11512341/803ffd0f0358/vaccines-12-01195-g011.jpg

相似文献

1
Comparative Efficacy of Parenteral and Mucosal Recombinant Probiotic Vaccines Against SARS-CoV-2 and Infections in Animal Models.肠胃外和粘膜重组益生菌疫苗对动物模型中 SARS-CoV-2 及感染的比较疗效
Vaccines (Basel). 2024 Oct 19;12(10):1195. doi: 10.3390/vaccines12101195.
2
SARS-CoV-2 Spike Protein-Expressing Enterococcus for Oral Vaccination: Immunogenicity and Protection.用于口服疫苗接种的表达严重急性呼吸综合征冠状病毒2刺突蛋白的肠球菌：免疫原性和保护作用
Vaccines (Basel). 2023 Nov 14;11(11):1714. doi: 10.3390/vaccines11111714.
3
Evaluation of Immune Response to Mucosal Immunization with an Oral Probiotic-Based Vaccine in Mice: Potential for Prime-Boost Immunization against SARS-CoV-2.评估口服益生菌疫苗对小鼠黏膜免疫的应答：作为 SARS-CoV-2 初免-加强免疫的潜力。
Int J Mol Sci. 2023 Dec 22;25(1):215. doi: 10.3390/ijms25010215.
4
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.XBB.1.5 rS 疫苗在叙利亚仓鼠中针对 SARS-CoV-2 的 EG.5.1 变异株的免疫原性和疗效。
J Virol. 2024 Oct 22;98(10):e0052824. doi: 10.1128/jvi.00528-24. Epub 2024 Sep 4.
5
Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models.联合肌内/鼻内 RAZI-COV 疫苗候选物对 SARS-CoV-2 的安全性和有效性：几种动物模型的临床前研究。
Front Immunol. 2022 May 26;13:836745. doi: 10.3389/fimmu.2022.836745. eCollection 2022.
6
Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.黏膜免疫接种基于腺病毒 5 的疫苗可保护叙利亚仓鼠免受 SARS-CoV-2 的奥密克戎和德尔塔变异株的挑战。
Front Immunol. 2023 Feb 22;14:1086035. doi: 10.3389/fimmu.2023.1086035. eCollection 2023.
7
Developing a Live Probiotic Vaccine Based on the L3 Strain Expressing Influenza Neuraminidase.基于表达流感神经氨酸酶的L3菌株开发一种活益生菌疫苗。
Microorganisms. 2021 Nov 27;9(12):2446. doi: 10.3390/microorganisms9122446.
8
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.SARS-CoV-2 S1 亚单位加强疫苗在老年小鼠中引发强烈的体液免疫应答。
Microbiol Spectr. 2023 Jun 15;11(3):e0436322. doi: 10.1128/spectrum.04363-22. Epub 2023 May 10.
9
Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.口服亚单位 SARS-CoV-2 疫苗可诱导全身中和 IgG、IgA 和细胞免疫应答，并能增强已接种疫苗产生的中和抗体应答。
Vaccine. 2022 Feb 16;40(8):1098-1107. doi: 10.1016/j.vaccine.2022.01.025. Epub 2022 Jan 19.
10
Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters.鼻腔内给予未佐剂的 SARS-CoV-2 刺突抗原可增强小鼠和仓鼠中经蛋白亚单位疫苗初免后的抗原特异性免疫应答。
Eur J Immunol. 2024 Jun;54(6):e2350620. doi: 10.1002/eji.202350620. Epub 2024 Apr 1.

引用本文的文献

1
Distinct humoral responses induced by heterologous versus homologous prime-boost immunization strategies in early life.早期生活中异源与同源初免-加强免疫策略诱导的不同体液反应。
Front Immunol. 2025 Aug 7;16:1563345. doi: 10.3389/fimmu.2025.1563345. eCollection 2025.
2
Carmofur Exhibits Antimicrobial Activity Against .卡莫氟对……具有抗菌活性。
Antibiotics (Basel). 2025 Feb 25;14(3):231. doi: 10.3390/antibiotics14030231.

本文引用的文献

1
The interaction of innate immune and adaptive immune system.先天免疫系统与适应性免疫系统的相互作用。
MedComm (2020). 2024 Sep 15;5(10):e714. doi: 10.1002/mco2.714. eCollection 2024 Oct.
2
Deciphering the Potential of Probiotics in Vaccines.解读益生菌在疫苗中的潜力。
Vaccines (Basel). 2024 Jun 26;12(7):711. doi: 10.3390/vaccines12070711.
3
Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice.鼻腔内接种 SARS-CoV-2 奥密克戎变异株疫苗可在雌性小鼠中诱导体液和细胞黏膜免疫。
EBioMedicine. 2024 Jul;105:105185. doi: 10.1016/j.ebiom.2024.105185. Epub 2024 Jun 7.
4
Recent development of oral vaccines (Review).口服疫苗的最新进展（综述）
Exp Ther Med. 2024 Mar 22;27(5):223. doi: 10.3892/etm.2024.12511. eCollection 2024 May.
5
Next-Generation Probiotics as Novel Therapeutics for Improving Human Health: Current Trends and Future Perspectives.下一代益生菌作为改善人类健康的新型疗法：当前趋势与未来展望
Microorganisms. 2024 Feb 20;12(3):430. doi: 10.3390/microorganisms12030430.
6
Vaccine Strategies to Elicit Mucosal Immunity.诱导黏膜免疫的疫苗策略。
Vaccines (Basel). 2024 Feb 13;12(2):191. doi: 10.3390/vaccines12020191.
7
Cholera toxin and O-specific polysaccharide immune responses after oral cholera vaccination with Dukoral in different age groups of Bangladeshi participants.口服 Dukoral 霍乱疫苗后不同年龄组孟加拉参与者的霍乱毒素和 O 特异性多糖免疫应答。
mSphere. 2024 Mar 26;9(3):e0056523. doi: 10.1128/msphere.00565-23. Epub 2024 Feb 23.
8
Expressing Murine Rotavirus VP8 and Mucosal Adjuvants Induce Virus-Specific Immune Responses.表达小鼠轮状病毒VP8和黏膜佐剂可诱导病毒特异性免疫反应。
Vaccines (Basel). 2023 Nov 28;11(12):1774. doi: 10.3390/vaccines11121774.
9
SARS-CoV-2 Spike Protein-Expressing Enterococcus for Oral Vaccination: Immunogenicity and Protection.用于口服疫苗接种的表达严重急性呼吸综合征冠状病毒2刺突蛋白的肠球菌：免疫原性和保护作用
Vaccines (Basel). 2023 Nov 14;11(11):1714. doi: 10.3390/vaccines11111714.
10
The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection.细菌和细菌衍生物作为病毒感染药物传递系统的潜在用途。
Virol J. 2023 Oct 3;20(1):222. doi: 10.1186/s12985-023-02183-z.